Inovio Pharmaceuticals (INO) vs PepGen (PEPG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Inovio Pharmaceuticals (INO) has outperformed PepGen (PEPG) over the past year, gaining 0.0% versus a loss of 32.0%. PepGen is the larger company by market cap ($356.3 million vs $329.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INO | PEPG |
|---|---|---|
| Share price | $1.76 | $3.78 |
| Market cap | $329.66M | $356.31M |
| 1-day change | +2.92% | -3.82% |
| YTD return | +1.15% | -41.94% |
| 1-year return | 0.00% | -32.01% |
| 5-year return | -97.98% | — |
| EPS (TTM) | $-0.59 | $-0.77 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $65.34K | — |
| Revenue growth (YoY) | -69.99% | — |
| Net income (latest FY) | $-84.95M | $-89.66M |
| Operating margin | -132871.32% | — |
| Net margin | -130000.00% | — |
| 52-week high | $2.72 | $7.80 |
| 52-week low | $0.56 | $1.31 |
| Distance from 52-week high | -35.29% | -51.54% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +259.66% | +263.76% |
| Average volume | 11.24M | 3.26M |
| Shares outstanding | 187.31M | 94.26M |
| Employees | 112 | 53 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INO has outperformed PEPG by 32.0 percentage points over the past year.
About Inovio Pharmaceuticals
INO stock →Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Health Care · Biotechnology: Pharmaceutical Preparations · 112 employees
About PepGen
PEPG stock →PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 53 employees
INO vs PEPG FAQ
Which is bigger, Inovio Pharmaceuticals or PepGen?
PepGen (PEPG) is larger, with a market capitalization of $356.31M compared with $329.66M for Inovio Pharmaceuticals (INO).
Which stock has performed better over the past year, INO or PEPG?
INO returned 0.00% over the past 12 months, compared with -32.01% for PEPG (price return, excluding dividends). Past performance does not predict future results.
Are Inovio Pharmaceuticals and PepGen in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.